Companies · Biotechnology

Arterica Inc.

SANTA ROSA · Biotechnology

Diligence memoA one-page analyst read on Arterica Inc. — recommendation, valuation, rhythm, risks.
$6.3M
Total raised · real
3
Rounds
3.1×
Latest step-up
Top 53%
Sector rank · raised
Seed
Latest stage · inferred · Fri May 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Arterica Inc. looks over-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.60× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.
At-risk
  • Last raise 3.1 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Arterica Inc. is one of 4293 Biotechnology companies tracked from SANTA ROSA. By capital raised it ranks mid-pack (ahead of 48% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2023-05-12
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2019-07-02 Raised $3.0M (real) Modeled valuation $133M (est)$3.0M$133MSeed2019Seed · 2021-10-25 Raised $805K (real) Modeled valuation $17M (est)$805K$17MSeed2021Seed · 2023-05-12 Raised $2.5M (real) Modeled valuation $23M (est)$2.5M$23MSeed2023+$805K+$2.5MCumulative $6.3M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.0M · 2019
Seed extension$805K · 2021
Seed extension$2.5M · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$22.8M
Base estimate est.
$1.8M
Conservative case
$82.5M
Upside case
$12.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $133.2M · 2019-07-022019Seed · modeled $17.2M · 2021-10-25Seed · modeled $22.8M · 2023-05-122023
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
3.1 yr
Elapsed time used
3.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
23 mo
Avg between rounds
$1.6M/yr
Capital velocity
7.0 yr
On record since
2019
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.9× of median
This company$6.3M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.4× above median
This company$2.5M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$22.8M
Sector median$64.2M

Raised more than 48% of sector peers (real $). Modeled value above 30% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #69 of 207.

This companyCohort peer
$10.0M$100.0M$1.0M$10.0MCapital raised (log)Mesentech Inc. · Seed Raised $3.9M · modeled $65.7M (est)Marlinspike Therapeutics, Inc. · Seed Raised $3.5M · modeled $64.4M (est)Microbial Machines, Inc. · Seed Raised $3.9M · modeled $63.7M (est)Pearl Diagnostics, Inc. · Seed Raised $3.5M · modeled $62.9M (est)Crossfire Medical Inc · Seed Raised $3.0M · modeled $57.5M (est)Design Pharmaceuticals, Inc. · Seed Raised $3.0M · modeled $57.0M (est)Tekv Holdings LLC · Seed Raised $4.0M · modeled $55.5M (est)Mi-Helper, Inc. · Seed Raised $4.0M · modeled $50.9M (est)Thelium Therapeutics Inc. · Seed Raised $3.1M · modeled $50.7M (est)Turtle Health, Inc. · Seed Raised $2.7M · modeled $49.1M (est)Accufix Holdings, Inc. · Seed Raised $4.2M · modeled $46.7M (est)Kyttaro Ltd · Seed Raised $5.2M · modeled $45.5M (est)Arterica Inc. (this company) Raised $6.3M · modeled $22.8M (est)Arterica Inc.
CompanyStageRaised · realValue · estvs peer med.
Mesentech Inc.Seed$3.9M$65.7M4.61×
Marlinspike Therapeutics, Inc.Seed$3.5M$64.4M4.52×
Microbial Machines, Inc.Seed$3.9M$63.7M4.47×
Pearl Diagnostics, Inc.Seed$3.5M$62.9M4.41×
Crossfire Medical IncSeed$3.0M$57.5M4.04×
Design Pharmaceuticals, Inc.Seed$3.0M$57.0M4.00×
Tekv Holdings LLCSeed$4.0M$55.5M3.89×
Mi-Helper, Inc.Seed$4.0M$50.9M3.58×
Thelium Therapeutics Inc.Seed$3.1M$50.7M3.56×
Turtle Health, Inc.Seed$2.7M$49.1M3.45×
Accufix Holdings, Inc.Seed$4.2M$46.7M3.28×
Kyttaro LtdSeed$5.2M$45.5M3.20×
Arterica Inc. this companySeed$6.3M$22.8M1.60×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.0M2019-07-02$15.0M$133.2M90%
Seed$805K2021-10-25$4.0M$17.2M90%
Seed$2.5M2023-05-12$12.5M$22.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.0M2019-07-02
    • First recorded raise — entered as Seed.
    • 1 investor on this round.
  2. Seed$805K2021-10-25
    • Raised again after 28 mo — slower than the ~14 mo sector norm.
    • Round 3.7× smaller than the prior — bridge or down round.
    • 10 investors on this round.
  3. Seed$2.5M2023-05-12
    • Raised 19 mo later, in step with the ~14 mo sector norm.
    • Round 3.1× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2025 ~Q2
Modeled next raise · ~23mo cadence
$7.5M
Modeled next size est.range $4.9M$12.0M
3.1×
Last step-up
$1.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert Whirley3 other2023-05
Joseph Humphrey1 other2023-05
ROBERT G. WHIRLEY1 other2019-07
CHARLIE A. RAMPERSAUD2021-10
Charlie G. Rampersaud2019-07
Charlie Rampersaud2023-05
JOSEPH A. HUMPHREY2021-10
THOMAS A. LARZON2021-10
Thomas G. Larzon2019-07
Thomas Larzon2023-05
THORSTEN A. SIESS2021-10
Thorsten G. Siess2019-07
Thorsten Siess2023-05
TOBIAS A. TULLBERG2021-10
Tobias G. Tullbert2019-07
Tobias Tullberg2023-05
Registry & provenance

Arterica Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1782224
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Jellatech, Inc.BiotechnologySeed$6.4M$27.3Msame sector · same stage
Imaging3 IncBiotechnologySeed$6.6M$19.1Msame sector · same stage
Pneumeric, Inc.BiotechnologySeed$5.7M$23.5Msame sector · same stage
e-Nicotine Technology, Inc.BiotechnologySeed$7.0M$17.8Msame sector · same stage
Virica Biotech Inc.BiotechnologySeed$7.0M$18.6Msame sector · same stage
TV2 HOLDING CoOther Health CareSeries C$173.7M$228.6Mnetwork3 shared operators
Gusto Global, LLCBiotechnologySeed$5.5M$24.3Msame sector · same stage
Arrogene, IncBiotechnologySeed$7.2M$23.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Artelo Biosciences, Inc.BiotechnologySeries A$723K93%
Artelon, Inc.BiotechnologySeries B$230.7M93%
Vascular Therapies IncBiotechnologySeries B$471.9M88%
Angion Biomedica Corp.BiotechnologySeries B$48.4M86%
Aortic Innovations LLCBiotechnologySeed$71.9M86%
Vascugen, Inc.BiotechnologySeries A$361.5M86%
Aortica CorpBiotechnologySeries A$37.1M86%
Access Vascular, Inc.BiotechnologySeries B$200.4M86%
Frequently asked
How much funding has Arterica Inc. raised?
Arterica Inc. has raised approximately $6.3M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Arterica Inc.'s estimated valuation?
Provath's modeled valuation for Arterica Inc. is approximately $22.8M (modeled range $1.8M–$82.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Arterica Inc. at?
Arterica Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Fri May 12.
What does Arterica Inc. do and where is it based?
Arterica Inc. operates in the Biotechnology sector, based in SANTA ROSA.
Explore related

See where Arterica Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Arterica Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.